# Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies

> **NCT01463982** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 21 (actual)

## Conditions studied

- Solid Tumor
- Advanced Cancer

## Interventions

- **DRUG:** Oratecan and Capecitabine

## Key facts

- **NCT ID:** NCT01463982
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-12
- **Primary completion:** 2012-04
- **Final completion:** 2013-12
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2015-04-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01463982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01463982, "Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01463982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*